Floatz logo

Detoxpc

Liver Cancer

National Cancer Institute (NCI)vaccinePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
65/ 100

Competitive context

112 Active assets in the Liver Cancer cohort.

Asset / SponsorPhaseRating
Bxcl501
Uppsala University Hospital
Phase 4BBB
Inno-206
Shanghai Zhongshan Hospital
Phase 4BB
Eloxatin
Sun Yat-sen University
Phase 3BB
Sorafenib
First Affiliated Hospital Xi'an Jiaotong University
Phase 3BB
S-Ketamine
The Second Affiliated Hospital of Chongqing Medical University
Phase 4BB

View all 50 →

Same molecule, other indications

Detoxpc is also rated in:

testicular germ cell tumorDormant
B
Indicative ·
57 / 100
View asset →
cutaneous melanomaDormant
B
Indicative ·
57 / 100
View asset →
cancer of unknown primary siteDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →